REFR vs REGN · rev $1.3M vs P/E 14, rev $14.34B
Research Frontiers Incorporated (REFR) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Research Frontiers Incorporated (REFR) is a electronic components company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported REFR revenue for 2024-12-31 was $1.3M. Net income was -$1.3M. Revenue was up 46.8% from 2023-12-31 to 2024-12-31. REFR currently screens at market cap $22.4M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
REFR currently screens at market cap $22.4M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the REFR and REGN stock pages for the full models.
Not investment advice.